Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Immunology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Atopic Dermatitis Clinical Trials

A listing of Atopic Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (170) clinical trials

Study of Adult Patients Receiving DUPIXENT for Atopic Dermatitis (AD)

This is a prospective observational study conducted to (1) characterize the patients who receive DUPIXENT for AD in a real world setting with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD; (2) characterize real world use patterns of DUPIXENT for AD (eg, ...

Phase N/A

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

4-week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of Three Concentrations (0.05%, 0.1% and 0.25%) of PUR 0110 (Thykamine) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis.

Phase

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged 2 Years With Mild-moderate AD

Approximately 600 subjects will be enrolled in the study, of which at least 150 subjects aged 2-6; at least 140 subjects aged 7-11; at least 120 subjects aged 12-17 and up to 90 subjects will be adults. Subjects must have mild-moderate AD involving at least 5% treatable %BSA assessed on ...

Phase

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

This will be a randomized, double-blind, placebo-controlled clinical study with dose escalations to assess safety, tolerability, and pharmacodynamic effect of EDP1066. Since this clinical study is the first study in humans, the participants will be healthy volunteers or subjects with mild to moderate psoriasis or atopic dermatitis who are otherwise ...

Phase

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Study of the long term safety of serlopitant for the treatment of pruritus in adults.

Phase

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and psoriasis. Subjects will be queried regarding adverse events (AEs) ...

Phase

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

This is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month open-label extension ...

Phase

BioDay Registry: Data Collection Regarding Dupixent in Patients With Atopic Dermatitis in Daily Practice

Atopic Dermatitis (AD) is the most common chronic inflammatory skin disease in the Netherlands with more than 400.000 patients suffering from this disease. For patients with difficult to treat AD, treatment options are limited. Although the Dutch AD Guideline recommends oral immunosuppressive drugs in difficult to treat AD, both label ...

Phase N/A

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients with Moderate to Severe Atopic Dermatitis. The study is multi center and will consist of two dose levels: Group A (n=9): patients will receive a total of 4 x 200mg subcutaneous injections of bermekimab. Dosing will occur ...

Phase

A Study Investigating the Efficacy Safety and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD

This is a multi-center, randomized, double blind, placebo controlled, parallel group, dose ranging study investigating the efficacy, safety, and pharmacokinetic profile of ANB020 administered to adult subjects with moderate-to-severe atopic dermatitis.

Phase